Lowest Price Guaranteed From USD 4,899
Published
July 2020
Pages
513
View Count
9484
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
 |
.PNG) |
 |
.PNG) |
.PNG) |
 |
 |
 |
 |
The overall market for digital therapeutics is expected to be worth over a billion dollars, and is likely to evolve significantly in the near future, as more of such solutions are developed and made available. Further, a significant surge in adoption of these evidence-based solutions can be observed due to increased demand for personalized treatment options amid COVID-19 outbreak
-- Founder and CEO, a UK based small-sized company
Chronic disorders, such as arthritis, diabetes, cancer, obesity and heart disease, are considered to be the leading causes of death and disability across the world. Specifically, the global prevalence of diabetes is estimated to be more than 300 million adults by 2025. According to the WHO, more than 450 million people are presently suffering from some form of mental health disorder (such as anxiety and depression), and / or neurological disorder. The rise in number of patients suffering from such clinical conditions continues to impose a significant burden on the global healthcare system. Specifically, in the US, it was estimated that approximately 90% of the country’s annual healthcare expenditure was on patients suffering from various chronic and mental health conditions.
Digital health solutions represent a relatively new concept, which was introduced into mainstream healthcare a few years ago. Such solutions are presently believed to possess the potential to reshape the practice of healthcare. Typically, digital therapeutics are available in the form of various types of gamified solutions, and / or standalone software applications, sometimes featuring active, personalized coaching support, or artificial intelligence (AI) enabled support. The ongoing COVID-19 pandemic and the mandatory enforcement of social distancing measures have created a significant demand for remote healthcare solutions. In fact, China introduced a range of digital solutions throughout different stages of the outbreak, immediately after the coronavirus spread. Recently, the USFDA also issued certain guidelines on usability of digital therapeutics (specifically for psychiatric conditions), allowing patients to receive treatment at home, minimizing visits to clinics / hospitals, thereby, reducing risk of exposure to the novel coronavirus. Moreover, several companies are actively striving to create and launch solutions that not only allow patients to diagnose and confirm disease symptoms, and consult with doctors / physicians remotely, but also offer therapeutic aid. Although the focus of such companies is presently on diabetes, mental health disorders and musculoskeletal injuries, experts believe that digital therapeutics may eventually replace / augment traditional treatment measures, with clinically validated software. ,
It is worth noting that there are several successful start-ups focused on designing and development of digital therapeutics; in fact, most such companies are backed by noteworthy investors. A number of digital health solutions are already in the market, and several other innovative solutions are under development. It is worth highlighting that for certain digital health solutions, reimbursement options are also available. In addition, several companies are focused on expanding their offerings to support the management of the COVID-19 pandemic. As the demand for digital solutions gradually rises, pioneers in this domain are likely to benefit the most from increased product sales.
The “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation))” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of digital therapeutics solutions (either commercialized or under development) in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and the future opportunity for digital therapeutics developers over the next decade. Based on multiple parameters, likely adoption trends, and expected price variations for these products, we have provided an informed estimate of the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within digital therapeutics market across [A] type of solution (combination offering of software application + device or AI or personal coach, and standalone software applications), [B] purpose of solution (medication replacement and medication augmentation), [C] type of therapy (curative and preventive), [D] distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), [E] therapeutic areas (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other disorders), and [F] key geographical regions (North America (the US and Canada), Europe (France, Germany, Italy, Spain and the UK), Asia-Pacific (Australia, China, India, Japan, and South Korea) and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of digital therapeutic solutions market and its likely evolution in the short-mid term and long term.
Chapter 3 provides a general overview of the digital health sector, covering details related to the current and future trends in the domain. The chapter highlights the key concepts related to digital therapeutics. It also features a discussion on strategic initiatives undertaken by several organizations to support the development of digital solutions for treatment of chronic disorders. The chapter also provides an overview of the various product development pathways adopted by the companies in this field.
Chapter 4 includes a detailed analysis of the current market landscape of over 230 digital therapeutic solutions, based on status of development, type of solution (combination offering of software application + device or AI or personal coach, and standalone software application), type of therapy (curative and preventive), purpose of solution (medication replacement and medication augmentation), target disease indication(s), therapeutic area(s), and target population. Further, the chapter provides an analysis of digital therapeutic solution developers, based on year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters. It also highlights the contemporary market trends in four schematic representations, which include [A] a bubble analysis comparing the leading players engaged in the development of digital therapeutic solutions based on the parameters, such as product portfolio strength, number of target indication(s) and company size, [B] a grid representation illustrating the distribution of the digital therapeutic solutions based on status of development, type of solution and therapeutic area, [C] an insightful tree map representation of the digital therapeutic solutions, distributed on the basis of therapeutic area and company size, and [D] a world map representation highlighting the regional distribution of developer companies.
Chapter 5 presents a detailed product competitiveness analysis of digital therapeutic solutions developed / under development for the most popular therapeutic areas taking into consideration the strength of product portfolio (based on the total number of digital therapeutic solutions being developed in that disease area) and key product specific parameters, such as status of development, type of solution, type of therapy, and purpose of solution.
Chapter 6 features elaborate profiles of prominent small-sized and mid-sized players that are either engaged in the development or have developed digital therapeutic solutions. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.
Chapter 7 provides a detailed analysis of more than 220 completed, ongoing and planned clinical studies of various digital therapeutic solutions, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status and trial focus, highlighting leading sponsors and leading digital therapeutic solutions (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful clinical end-points analysis (for trials initiated since 2018 for popular therapeutic areas).
Chapter 8 features an analysis of the investments made in the period between 2009 and 2020 (till June), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.
Chapter 9 features an in-depth analysis and discussion on the various partnerships inked between the players in this market, during the period, 2008-2020 (till May), covering marketing and distribution agreements, mergers / acquisitions, pilot product offerings, product / technology integration agreements, product / technology licensing agreements, product development agreements, product evaluation agreements, product training agreements, research and development agreements and product development and commercialization agreements.
Chapter 10 features a detailed analysis on the various business models and go-to-market strategies adopted by companies involved in this space. It also provides details on various channels adopted / being adopted by stakeholders in the industry to raise awareness and offer access to their proprietary products.
Chapter 11 presents a Bowman’s Strategy Clock framework in order to analyze the competitive position of various companies in the marketplace, taking into consideration the prices and different features of their products.
Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of digital therapeutic solutions market till 2030. We have segmented the market across [A] type of solution (combination offering of software application + device or AI or personal coach, and standalone software applications), [B] purpose of solution (medication replacement and medication augmentation), [C] type of therapy (curative and preventive), [D] distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), [E] therapeutic areas (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other disorders), and [F] key geographical regions (North America (the US and Canada), Europe (France, Germany, Italy, Spain and the UK), Asia-Pacific (Australia, China, India, Japan, and South Korea) and rest of the world).
Chapter 13 highlights the impact of COVID-19 outbreak on the overall digital therapeutics market. In addition, it features a brief discussion on the key initiatives undertaken by big pharma players.
Chapter 14 features a review of the of the key aspects related to the remote digital monitoring and diagnostics solutions, including [A] a brief introduction to remote digital monitoring and diagnostics solutions, highlighting the key benefits and roadblocks [B] an assessment of the market landscape of remote digital monitoring and diagnostics solutions, based on various parameters, such as status of development, type of solution, target disease indication(s) and therapeutic area, along with the details on the companies that develop these solutions, highlighting year of establishment, company size and location of headquarters [C] detailed profiles of some of the key players that presently offer digital monitoring / diagnostic solutions for chronic disease management; each profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters, lead investors, key partners and members of the executive team), details of their product portfolio, recent developments and an informed future outlook, and [D] an insightful analysis on various capital investments that have been made into the digital monitoring / diagnostics domain.
Chapter 15 presents a discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall digital therapeutic solutions industry.
Chapter 16 offers an informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till July) and insights from the recent news articles related digital therapeutic solutions, indicating the increasing popularity of this domain. Furthermore, it highlights the potential future opportunities for players engaged in the development of such solutions.
Chapter 17 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health), Adam Kaufman (Chief Executive Officer, Canary Health), Vijay Ravindran (Chief Executive Officer, Floreo), Eran Ofir (Chief Executive Officer, Somatix), Edouard Gasser (Chief Executive Officer, Tilak Healthcare), Palakh R Sarogi (Vice President Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics), Amelie Janson (Communication Manager, Voluntis), and Anonymous (Founder and Chief Executive Officer, UK based Small-Sized Company).
Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 19 is an appendix, which contains the list of companies and organizations mentioned in the report
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
3.5.2. Product Development and Commercialization Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Prescription Requirement
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4 Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number of Digital Therapeutics Solutions
4.6. Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
4.7. Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area
4.8. Tree Map Representation: Analysis by Therapeutic Area and Company Size
4.9. World Map Representation: Analysis of Regional Activity
4.10. Digital Therapeutics: Information on Additional Companies
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.4. Key Therapeutic Areas
5.4.1. Cardiovascular Disorders
5.4.1.1. Product Competitiveness Analysis
5.4.2. Mental Health Problems
5.4.2.1. Product Competitiveness Analysis
5.4.3. Metabolic Disorders
5.4.3.1. Product Competitiveness Analysis
5.4.4. Neurological Disorders
5.4.4.1. Product Competitiveness Analysis
5.4.5. Substance Use Disorders
5.4.5.1. Product Competitiveness Analysis
5.4.6. Other Therapeutic Areas
5.4.6.1. Product Competitiveness Analysis
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5 Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Mindmaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled and Trial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Players: Analysis by Number of Registered Trials
7.3.8 Leading Digital Therapeutic Solutions: Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Geographical Analysis by Number of Clinical Trials
7.3.12. Geographical Analysis by Trial Recruitment Status
7.3.13. Geographical Analysis by Enrolled Patient Population
7.4. Clinical End-Points Analysis
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Digital Therapeutics: Funding and Investment Analysis
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Therapy
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Geography
8.3.7. Most Active Players: Analysis by Number of Funding Instances
8.3.8. Most Active Players: Analysis by Amount of Funding
8.3.9. Most Active Investors: Analysis by Number of Instances
8.4 Concluding Remarks
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: Recent Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Type of Partnership and Year of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Type of Partner and Year of Partnership
9.3.3.2. Analysis by Type of Partner and Type of Partnership
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Therapy and Type of Partnership
9.3.4.2. Analysis by Type of Therapy and Type of Partner
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Therapeutic Area and Year of Partnership
9.3.5.2 Analysis by Therapeutic Area and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and Intracontinental Agreements
10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models and Pricing Strategies
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model
10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks
11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3 Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2020-2030
12.4. Global Digital Therapeutics Market: Distribution by Type of Solution
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2020-2030
12.4.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2020-2030
12.4.3. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2020-2030
12.4.4. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2020-2030
12.4.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2020-2030
12.4.6. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2020-2030
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2020-2030
12.5. Global Digital Therapeutics Market: Distribution by Purpose of Solution
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2020-2030
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2020-2030
12.6. Global Digital Therapeutics Market: Distribution by Type of Therapy
12.6.1 Digital Therapeutics Market for Curative Therapy, 2020-2030
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2020-2030
12.7. Global Digital Therapeutics Market: Distribution by Business Model
12.7.1. Digital Therapeutics Market for B2C Model (Patients and Caregivers), 2020-2030
12.7.2. Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2020-2030
12.8. Global Digital Therapeutics Market: Distribution by Therapeutic Area
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2020-2030
12.8.2. Digital Therapeutics Market for Chronic Pain, 2020-2030
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2020-2030
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2020-2030
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2020-2030
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2020-2030
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2020-2030
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2020-2030
12.8.9. Digital Therapeutics Market for Other Disorders, 2020-2030
12.9. Global Digital Therapeutics Market: Distribution by Geography
12.9.1 Digital Therapeutics Market in North America, 2020-2030
12.9.1.1 Digital Therapeutics Market in the US, 2020-2030
12.9.1.2 Digital Therapeutics Market in Canada, 2020-2030
12.9.2 Digital Therapeutics Market in Europe, 2020-2030
12.9.2.1. Digital Therapeutics Market in France, 2020-2030
12.9.2.2. Digital Therapeutics Market in Germany, 2020-2030
12.9.2.3. Digital Therapeutics Market in Italy, 2020-2030
12.9.2.4. Digital Therapeutics Market in Spain, 2020-2030
12.9.2.5. Digital Therapeutics Market in the UK, 2020-2030
12.9.2.6. Digital Therapeutics Market in Rest of Europe, 2020-2030
12.9.3. Digital Therapeutics Market in Asia-Pacific, 2020-2030
12.9.3.1. Digital Therapeutics Market in Australia, 2020-2030
12.9.3.2. Digital Therapeutics Market in China, 2020-2030
12.9.3.3. Digital Therapeutics Market in India, 2020-2030
12.9.3.4. Digital Therapeutics Market in Japan, 2020-2030
12.9.3.5. Digital Therapeutics Market in South Korea, 2020-2030
12.9.3.6. Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030
12.9.4. Digital Therapeutics Market in Rest of the World, 2020-2030
13. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
13.1. Chapter Overview
13.2. Impact of Coronavirus Pandemic on Digital Therapeutics
13.2.1. Impact on Future Market Opportunity for Digital Therapeutic Solutions Market
13.3. Recuperative Strategies for Developer Businesses
13.3.1. Strategies for Implementation in the Short / Mid Term
13.3.2. Strategies for Implementation in the Long Term
14. REMOTE DIGITAL MONITORING / DIAGNOSTIC SOLUTIONS
14.1. Chapter Overview
14.2. An Introduction to Remote Digital Monitoring / Diagnostic Solutions
14.3. Remote Digital Monitoring / Diagnostic Solutions: Overall Market Landscape
14.3.1. Analysis by Status of Development
14.3.2. Analysis by Type of Solution
14.3.3. Analysis by Target Disease Indication(s)
14.3.4. Analysis by Therapeutic Area
14.3.5. Grid Representation: Analysis by Status of Development, Type of Solution, and Therapeutic Area
14.4. Remote Digital Monitoring / Diagnostic Solutions: List of Developers
14.4.1. Analysis by Year of Establishment
14.4.2. Analysis by Company Size
14.4.3. Analysis by Location of Headquarters
14.5. Remote Digital Monitoring / Diagnostic Solutions: Company Profiles
14.5.1. AliveCor
14.5.1.1. Company Snapshot
14.5.1.2. Product Portfolio
14.5.1.3. Recent Developments and Future Outlook
14.5.2. Bioserenity
14.5.2.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook
14.5.3. Cue
14.5.3.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook
14.5.4. Kinsa
14.5.4.1. Company Snapshot
14.5.4.2. Product Portfolio
14.5.4.3. Recent Developments and Future Outlook
14.6. Remote Digital Monitoring / Diagnostic Solutions: Funding and Investment Analysis
14.6.1. Types of Funding
14.6.2. Remote Digital Monitoring / Diagnostic Solutions: List of Funding and Investments
14.6.2.1. Analysis by Number of Funding Instances
14.6.2.2. Analysis by Amount Invested
14.6.2.3. Analysis by Type of Funding
14.6.2.4. Most Active Players: Analysis by Number of Funding Instances
14.6.2.5. Most Active Players: Analysis by Amount Invested
14.6.2.6. Most Active Investors: Analysis by Number of Funding Instances
14.7. Concluding Remarks
15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Comparison of SWOT Factors
15.2.1. Strengths
15.2.2. Weaknesses
15.2.3. Opportunities
15.2.4. Threats
16. DIGITAL SOLUTIONS: RECENT TRENDS AND FUTURE OPPORTUNITIES
16.1. Chapter Overview
16.2. Prevalent Trends Related to Digital Therapeutics
16.2.1. Emerging Focus Areas
16.2.2. Key Historical Trends
16.2.3. Geographical Distribution of Activity
16.3. Trends Shaping the Future of Digital Therapeutics
16.3.1. Digital Solutions Closing the Digital Gap
16.3.2. Increasing Focus on Patient Centric Models
16.3.3. Applicability across a Variety of Disease Indications
16.3.4. Increasing Emphasis on Real-World Evidence in Research and Development
16.3.5. Advances in IT and Computing Power to Foster Future Innovation
16.4. Improving the Future Health: Opportunities Beyond Digital Therapeutics
17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Vida Health
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Stephanie Tilenius, Co-Founder and Chief Executive Officer
17.3. Canary Health
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Adam Kaufman, Chief Executive Officer
17.4. Floreo
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Vijay Ravidran, Chief Executive Officer
17.5. Somatix
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Eran Ofir, Chief Executive Officer
17.6. Tilak Healthcare
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Edouard Gasser, Chief Executive Officer
17.7. Wellthy Therapeutics
17.7.1. Company Snapshot
17.7.2. Interview Transcript: Palakh R Saraogi, Vice President Marketing, Arani Sarkra, Senior Manager Consumer Marketing, and Yolande D’Mello, Marketing and Public Relations
17.8. Voluntis
17.8.1. Company Snapshot
17.8.2. Interview Transcript: Amelie Janson, Communications Manager
17.9. Anonymous
17.9.1. Interview Transcript: Anonymous, Founder and Chief Executive Officer
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Major Causes for Chronic Diseases
Figure 3.2 Historical Timeline of Digital Health: Analysis of Google Trends
Figure 3.3 Internet of Things: General Framework
Figure 3.4 Internet of Things: Applications in Healthcare
Figure 3.5 Prescription Digital Therapeutics: Process Map
Figure 3.6 Characteristics of a Digital Therapeutic Program: An Illustration
Figure 4.1 Digital Therapeutics: Distribution by Status of Development
Figure 4.2 Digital Therapeutics: Distribution by Approval Year
Figure 4.3 Digital Therapeutics: Distribution by Type of Solution
Figure 4.4 Digital Therapeutics: Distribution by Type of Therapy
Figure 4.5 Digital Therapeutics: Distribution by Purpose of Solution
Figure 4.6 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Figure 4.7 Digital Therapeutics: Distribution by Target Indication(s)
Figure 4.8 Digital Therapeutics: Distribution by Therapeutic Area
Figure 4.9 Digital Therapeutics: Distribution by Target Population
Figure 4.10 Digital Therapeutics: Distribution by Prescription Requirement
Figure 4.11 Digital Therapeutics: Distribution by Duration of Course
Figure 4.12 Digital Therapeutics: Distribution by Cost of Solution
Figure 4.13 Digital Therapeutics Developers: Distribution by Year of Establishment
Figure 4.14 Digital Therapeutics Developers: Distribution by Company Size
Figure 4.15 Digital Therapeutics Developers: Distribution by Business Model Used
Figure 4.16 Digital Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.17 Leading Developers: Analysis by Number of Digital Therapeutics Solutions
Figure 4.18 Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
Figure 4.19 Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area
Figure 4.20 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Figure 4.21 World Map Representation: Regional Activity of Developers
Figure 5.1 Cardiovascular Disorders: Shift in Trends (2018 to 2020)
Figure 5.2 Product Competitiveness Analysis: Cardiovascular Disorders
Figure 5.3 Mental Health Problems: Shift in Trends (2018 to 2020)
Figure 5.4 Product Competitiveness Analysis: Mental Health Problems
Figure 5.5 Metabolic Disorders: Shift in Trends (2018 to 2020)
Figure 5.6 Product Competitiveness Analysis: Metabolic Disorders
Figure 5.7 Neurological Disorders: Shift in Trends (2018 to 2020)
Figure 5.8 Product Competitiveness Analysis: Neurological Disorders
Figure 5.9 Substance Use Disorders: Shift in Trends (2018 to 2020)
Figure 5.10 Product Competitiveness Analysis: Substance Use Disorders
Figure 5.11 Other Therapeutic Areas: Shift in Trends (2018 to 2020)
Figure 5.12 Product Competitiveness Analysis: Other Therapeutic Areas
Figure 6.1 Akili Interactive: Core Technologies and Benefits of Digital Products
Figure 6.2 WellDoc: Key Benefits of Diabetes Management Program
Figure 6.3 Wellthy Therapeutics: Diabetes Program
Figure 7.1 Key Methods to Validate Digital Therapeutic Solutions
Figure 7.2 Clinical Trial Analysis: Scope and Methodology
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled, Pre-2011-2020
Figure 7.6 Clinical Trial Analysis: Distribution by Study Design
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.8 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.10 Clinical Trial Analysis: Leading Industry Players
Figure 7.11 Clinical Trial Analysis: Leading Digital Therapeutic Solutions
Figure 7.12 Clinical Trial Analysis: Distribution by Focus Area
Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 7.15 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Therapeutic Area
Figure 7.16 Clinical Trial Analysis: Year-Wise Trend in Number of Patients Enrolled (in thousands) for Popular Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.20 Clinical Trials Analysis: Key Clinical End-Points for Metabolic Disorders
Figure 7.21 Clinical Trial Analysis: Primary and Secondary Clinical End-Points for Metabolic Disorders
Figure 8.1 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Pre-2014-June-2020
Figure 8.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-June 2020
Figure 8.3 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-June 2020 (USD Million)
Figure 8.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-June 2020
Figure 8.5 Funding and Investment Analysis: Year-Wise Distribution by Type of Funding Pre-2014-June 2020
Figure 8.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-June 2020 (USD Million)
Figure 8.7 Funding and Investment Analysis: Year-Wise Distribution of Amount Invested and Type of Funding, Pre-2014-June 2020 (USD Million)
Figure 8.8 Funding and Investment Analysis: Summary of Amount Invested, Pre-2014-June 2020 (USD Million)
Figure 8.9 Funding and Investment Analysis: Distribution by Instances and Amount Invested by Type of Therapy, Pre-2014-June 2020 (USD Million)
Figure 8.10 Funding and Investment Analysis: Year-Wise Distribution of Instances by Type of Therapy, Pre-2014-June 2020
Figure 8.11 Funding and Investment Analysis: Cumulative Amount Invested (USD Million) by Type of Therapy, Pre-2014-June 2020
Figure 8.12 Funding and Investment Analysis: Distribution by Therapeutic Area, Pre-2014-June 2020
Figure 8.13 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, Pre-2014-June2020 (USD Million)
Figure 8.14 Funding and Investment Analysis: Distribution by Geography
Figure 8.15 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-June 2020
Figure 8.16 Most Active Players: Distribution by Number of Funding Instances, Pre-2014-June 2020
Figure 8.17 Most Active Players: Distribution by Amount Raised (USD Million), Pre-2014-June 2020
Figure 8.17 Most Active Investors: Distribution by Number of Funding Instances
Figure 8.18 Funding and Investment Summary, Pre-2014-Q1 2020 (USD Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2013-May 2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Therapy
Figure 9.10 Partnerships and Collaborations: Distribution by Type of Therapy and Type of Partnership
Figure 9.11 Partnerships and Collaborations: Distribution by Distribution by Type of Therapy and Type of Partner
Figure 9.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.13 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Figure 9.14 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Figure 9.15 Most Active Players: Distribution by Number of Partnerships
Figure 9.16 Partnerships and Collaborations: Regional Distribution
Figure 9.17 Partnerships and Collaborations: Country-Wise Distribution
Figure 9.18 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Go-to-Market Strategy: Commonly Used Social Media Platforms
Figure 10.2 Go-to-Market Strategy: Online / Print Media Platforms
Figure 10.3 Go-to-Market Strategy: Promotional Activities through Official Websites
Figure 10.4 Go-to-Market Strategy: Different Business Models Adopted
Figure 10.5 Go-to-Market Strategy: Promotional Activities through Product Websites
Figure 10.6 Go-to-Market Strategy: Key Marketing Strategies for New Entrants
Figure 10.7 Go-to-Market Strategy: Industry Stakeholder Opinions
Figure 11.1 Digital Therapeutics: Bowman Clock Pricing Strategy Matrix
Figure 11.2 Digital Therapeutics: Bowman Clock Pricing Strategy Graphical Interpretation
Figure 12.1 Overall Digital Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Figure 12.2 Global Digital Therapeutics Market: Distribution by Type of Solution, 2020 and 2030
Figure 12.3 Digital Therapeutics Market for Standalone Software Applications, 2020-2030 (USD Million)
Figure 12.4 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2020-2030 (USD Million)
Figure 12.5 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2020-2030 (USD Million)
Figure 12.6 Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2020-2030 (USD Million)
Figure 12.7 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2020-2030 (USD Million)
Figure 12.8 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2020-2030 (USD Million)
Figure 12.9 Digital Therapeutics Market for Other Type of Solutions, 2020-2030 (USD Million)
Figure 12.10 Global Digital Therapeutics Market: Distribution by Purpose of Solution, 2020 and 2030
Figure 12.11 Digital Therapeutics Market for Medication Replacement Solutions, 2020-2030 (USD Million)
Figure 12.12 Digital Therapeutics Market for Medication Augmentation Solutions, 2020-2030 (USD Million)
Figure 12.13 Global Digital Therapeutics Market: Distribution by Type of Therapy, 2020 and 2030
Figure 12.14 Digital Therapeutics Market for Curative Therapy, 2020-2030 (USD Million)
Figure 12.15 Digital Therapeutics Market for Preventive Therapy, 2020-2030 (USD Million)
Figure 12.16 Global Digital Therapeutics Market: Distribution by Business Model, 2020 and 2030
Figure 12.17 Digital Therapeutics Market for B2C Model (Patients and Caregivers), 2020-2030 (USD Million)
Figure 12.18 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2020-2030 (USD Million)
Figure 12.19 Global Digital Therapeutics Market: Distribution by Therapeutic Area, 2020 and 2030
Figure 12.20 Digital Therapeutics Market for Cardiovascular Disorders, 2020-2030 (USD Million)
Figure 12.21 Digital Therapeutics Market for Chronic Pain, 2020-2030 (USD Million)
Figure 12.22 Digital Therapeutics Market for Mental Health Problems, 2020-2030 (USD Million)
Figure 12.23 Digital Therapeutics Market for Metabolic Disorders, 2020-2030 (USD Million)
Figure 12.24 Digital Therapeutics Market for Neurological Disorders, 2020-2030 (USD Million)
Figure 12.25 Digital Therapeutics Market for Respiratory Disorders, 2020-2030 (USD Million)
Figure 12.26 Digital Therapeutics Market for Sleep Disorders, 2020-2030 (USD Million)
Figure 12.27 Digital Therapeutics Market for Substance Use Disorders, 2020-2030 (USD Million)
Figure 12.28 Digital Therapeutics Market for Other Disorders, 2020-2030 (USD Million)
Figure 12.29 Global Digital Therapeutics Market: Distribution by Geography, 2020 and 2030
Figure 12.30 Digital Therapeutics Market in North America, 2020-2030 (USD Million)
Figure 12.31 Digital Therapeutics Market in the US, 2020-2030 (USD Million)
Figure 12.32 Digital Therapeutics Market in Canada, 2020-2030 (USD Million)
Figure 12.33 Digital Therapeutics Market in Europe, 2020-2030 (USD Million)
Figure 12.34 Digital Therapeutics Market in France, 2020-2030 (USD Million)
Figure 12.35 Digital Therapeutics Market in Germany, 2020-2030 (USD Million)
Figure 12.36 Digital Therapeutics Market in Italy, 2020-2030 (USD Million)
Figure 12.37 Digital Therapeutics Market in Spain, 2020-2030 (USD Million)
Figure 12.38 Digital Therapeutics Market in the UK, 2020-2030 (USD Million)
Figure 12.39 Digital Therapeutics Market in Rest of Europe, 2020-2030 (USD Million)
Figure 12.40 Digital Therapeutics Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 12.41 Digital Therapeutics Market in Australia, 2020-2030 (USD Million)
Figure 12.42 Digital Therapeutics Market in China, 2020-2030 (USD Million)
Figure 12.43 Digital Therapeutics Market in India, 2020-2030 (USD Million)
Figure 12.44 Digital Therapeutics Market in Japan, 2020-2030 (USD Million)
Figure 12.45 Digital Therapeutics Market in South Korea, 2020-2030 (USD Million)
Figure 12.46 Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030 (USD Million)
Figure 12.47 Digital Therapeutics Market in Rest of the World, 2020-2030 (USD Million)
Figure 12.48 Global Digital Therapeutics Market, 2020-2030: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 13.1 Global Digital Therapeutics Market 2020-2030: COVID-19 Impact Informed Scenario (USD Billion)
Figure 14.1 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Figure 14.2 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Figure 14.3 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Target Disease Indication
Figure 14.4 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Therapeutic Area
Figure 14.5 Grid Representation: Distribution by Status of Development, Type of Solution, and Therapeutic Area
Figure 14.6 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Year of Establishment
Figure 14.7 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Company Size
Figure 14.8 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Location of Headquarters
Figure 14.9 AliveCor: Benefits of Kardia
Figure 14.10 Cue: Key Elements of Digital Monitoring / Diagnostic Solutions
Figure 14.11 Kinsa: Product Portfolio
Figure 14.12 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Number of Funding Instances by Year
Figure 14.13 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested (USD Million)
Figure 14.14 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Instances by Type of Funding
Figure 14.15 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 14.16 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Funding Instances
Figure 14.17 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested (USD Million)
Figure 14.18 Remote Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Funding Instances
Figure 15.1 Digital Therapeutics SWOT Analysis: Overview
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Emerging Focus Areas: Google News
Figure 16.2 Digital Therapeutics: Analysis of Google Trends
Figure 16.3 Geographical Activity: Analysis of Google Trends
Figure 16.4 Digital Health: Opportunities beyond Digital Therapeutics
Table 4.1 Digital Therapeutics: Information on Status of Development and Launch Year
Table 4.2 Digital Therapeutics: Information on Type of Solution
Table 4.3 Digital Therapeutics: Information on Type of Therapy and Purpose of Solution
Table 4.4 Digital Therapeutics: Information on Information on Target Indication(s), Therapeutic Area and Target Population
Table 4.5 Digital Therapeutic Solutions: Information on Prescription Requirement, Duration of Course and Cost of Solution
Table 4.4 Digital Therapeutics: List of Developers
Table 6.1 Digital Therapeutics: List of Companies Profiled
Table 6.2 Akili Interactive: Company Snapshot
Table 6.3 Akili Interactive: Digital Therapeutic Solutions Portfolio
Table 6.4 Akili Interactive: Recent Developments and Future Outlook
Table 6.5 Big Health: Company Snapshot
Table 6.6 Big Health: Digital Therapeutic Solutions Portfolio
Table 6.7 Big Health: Recent Developments and Future Outlook
Table 6.8 dreem: Company Snapshot
Table 6.9 dreem: Digital Therapeutic Solutions Portfolio
Table 6.10 dreem: Recent Developments and Future Outlook
Table 6.11 Kaia Health: Company Snapshot
Table 6.12 Kaia Health: Digital Therapeutic Solutions Portfolio
Table 6.13 Kaia Health: Recent Developments and Future Outlook
Table 6.14 Mindmaze: Company Snapshot
Table 6.15 Mindmaze: Digital Therapeutic Solutions Portfolio
Table 6.16 Omada Health: Company Snapshot
Table 6.17 Omada Health: Digital Therapeutic Solutions Portfolio
Table 6.18 Omada Health: Recent Developments and Future Outlook
Table 6.19 Pear Therapeutics: Company Snapshot
Table 6.20 Pear Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.21 Pear Therapeutics: Recent Developments and Future Outlook
Table 6.22 Vida Health: Company Snapshot
Table 6.23 Vida Health: Digital Therapeutic Solutions Portfolio
Table 6.24 Vida Health: Recent Developments and Future Outlook
Table 6.25 Voluntis: Company Snapshot
Table 6.26 Voluntis: Digital Therapeutic Solutions Portfolio
Table 6.27 Voluntis: Recent Developments and Future Outlook
Table 6.28 Welldoc: Company Snapshot
Table 6.29 Welldoc: Digital Therapeutic Solutions Portfolio
Table 6.30 Welldoc: Recent Developments and Future Outlook
Table 6.31 Wellthy Therapeutics: Company Snapshot
Table 6.32 Wellthy Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.33 Wellthy Therapeutics: Recent Developments and Future Outlook
Table 8.1 Digital Therapeutics: Funding and Investments, Information on Year of Investment, Type of Funding, Amount and Investor, till June 2020
Table 8.2 Digital Therapeutics: Funding and Investments, Information on Year of Establishment, Location of Headquarters of Recipients, Type of Therapy, and Therapeutic Area
Table 9.1 Digital Therapeutics: List of Collaborations, till May 2020
Table 9.2 Digital Therapeutics: Partnerships and Collaborations, Information on Type of Agreement (Region-wise and Geography-wise), till May 2020
Table 10.1 Digital Therapeutics: Summary of Marketing Strategies
Table 10.2 Go-to-Market Strategy: Product Specific Websites
Table 14.1 Remote Digital Monitoring / Diagnostic Solutions: List of Solutions
Table 14.2 Remote Digital Monitoring / Diagnostic Solutions: Information on Type of Solution
Table 14.3 Remote Digital Monitoring / Diagnostic Solutions: Information on Primary Disease Indication, Therapeutic Area and Diagnosis Indicators
Table 14.4 Remote Digital Monitoring / Diagnostic Solutions: List of Developers
Table 14.5 AliveCor: Company Snapshot
Table 14.6 AliveCor: Recent Developments and Future Outlook
Table 14.7 BioSerenity: Company Snapshot
Table 14.8 BioSerenity: Recent Developments and Future Outlook
Table 14.9 Cue: Company Snapshot
Table 14.10 Kinsa: Company Snapshot
Table 14.11 Kinsa: Recent Developments and Future Outlook
Table 14.12 Remote Digital Monitoring / Diagnostic Solutions: Funding and Investments
Table 14.13 Remote Digital Monitoring / Diagnostic Solutions: Summary of Investments
Table 17.1 Vida Health: Company Snapshot
Table 17.2 Canary Health: Company Snapshot
Table 17.3 Floreo: Company Snapshot
Table 17.4 Somatix: Company Snapshot
Table 17.5 Tilak Healthcare: Company Snapshot
Table 17.6 Wellthy Therapeutics: Company Snapshot
Table 17.7 Voluntis: Company Snapshot
Table 18.1 Digital Therapeutics: Distribution by Status of Development
Table 18.2 Digital Therapeutics: Distribution by Type of Solution
Table 18.3 Digital Therapeutics: Distribution by Type of Therapy
Table 18.4 Digital Therapeutics: Distribution by Purpose of Solution
Table 18.5 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Table 18.6 Digital Therapeutics: Distribution by Target Indication(s)
Table 18.7 Digital Therapeutics: Distribution by Therapeutic Area
Table 18.8 Digital Therapeutics: Distribution by Target Population
Table 18.9 Digital Therapeutics: Distribution by Prescription Requirement
Table 18.10 Digital Therapeutics: Distribution by Duration of Course
Table 18.11 Digital Therapeutics: Distribution by Cost of Solution
Table 18.12 Digital Therapeutics Developers: Distribution by Year of Establishment
Table 18.13 Digital Therapeutics Developers: Distribution by Company Size
Table 18.14 Digital Therapeutics Developers: Distribution by Business Model Used
Table 18.15 Digital Therapeutics Developers: Distribution by Location of Headquarters
Table 18.16 Leading Developers: Analysis by Number of Digital Therapeutics Solutions
Table 18.17 Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
Table 18.18 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Table 18.19 World Map Representation: Regional Activity of Developers
Table 18.20 Cardiovascular Disorders: Shift in Trends (2018 to 2020)
Table 18.21 Mental Health Problems: Shift in Trends (2018 to 2020)
Table 18.22 Metabolic Disorders: Shift in Trends (2018 to 2020)
Table 18.23 Neurological Disorders: Shift in Trends (2018 to 2020)
Table 18.24 Substance Use Disorders: Shift in Trends (2018 to 2020)
Table 18.25 Other Therapeutic Areas: Shift in Trends (2018 to 2020)
Table 18.26 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020
Table 18.27 Clinical Trial Analysis: Distribution by Trial Phase
Table 18.28 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled, Pre-2011-2020
Table 18.29 Clinical Trial Analysis: Distribution by Study Design
Table 18.30 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 18.31 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 18.32 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 18.33 Clinical Trial Analysis: Leading Industry Players
Table 18.34 Clinical Trial Analysis: Leading Digital Therapeutic Solutions
Table 18.35 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 18.36 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 18.37 Clinical Trial Analysis: Distribution by Number of Patients Enrollment and Therapeutic Area
Table 18.38 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollments (in thousands) for Popular Therapeutic Areas
Table 18.39 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 18.40 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Table 18.41 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 18.42 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Pre-2014-June-2020
Table 18.43 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-June 2020
Table 18.44 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-June 2020 (USD Million)
Table 18.45 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-June 2020
Table 18.46 Funding and Investment Analysis: Year-Wise Distribution by Type of Funding, Pre-2014-June 2020
Table 18.47 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-June 2020 (USD Million)
Table 18.48 Funding and Investment Analysis: Year-Wise Distribution of Amount Invested and Type of Funding, Pre-2014-June 2020 (USD Million)
Table 18.49 Funding and Investment Analysis: Summary of Amount Invested, Pre-2014-June 2020 (USD Million)
Table 18.50 Funding and Investment Analysis: Distribution by Instances and Amount Invested by Type of Therapy, Pre-2014-June 2020 (USD Million)
Table 18.51 Funding and Investment Analysis: Year-Wise Distribution of Instances by Type of Therapy, Pre-2014-June 2020
Table 18.52 Funding and Investment Analysis: Cumulative Amount Invested (USD Million) by Type of Therapy, Pre-2014-June 2020
Table 18.53 Funding and Investment Analysis: Distribution by Therapeutic Area, Pre-2014-June 2020 (USD Million)
Table 18.54 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, Pre-2014-April 2020 (USD Million)
Table 18.55 Funding and Investment Analysis: Distribution by Geography
Table 18.56 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-June 2020
Table 18.57 Most Active Players: Distribution by Number of Funding, Pre-2014-June 2020
Table 18.58 Most Active Players: Distribution by Number of Amount Raised (USD Million), Pre-2014-June 2020
Table 18.59 Most Active Investors: Distribution by Number of Funding Instances
Table 18.60 Funding and Investment Summary, Pre-2014-June 2020 (USD Million)
Table 18.61 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2014-May 2020
Table 18.62 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.63 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 18.64 Partnerships and Collaborations: Distribution by Type of Partnership and Partner
Table 18.65 Partnerships and Collaborations: Distribution by Type of Partner
Table 18.66 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Table 18.67 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Table 18.68 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Table 18.69 Partnerships and Collaborations: Distribution by Type of Therapy
Table 18.70 Partnerships and Collaborations: Distribution by Type of Therapy and Type of Partnership
Table 18.71 Partnerships and Collaborations: Distribution by Distribution by Type of Therapy and Type of Partner
Table 18.72 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 18.73 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Table 18.74 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Table 18.75 Most Active Players: Distribution by Number of Partnerships
Table 18.76 Partnerships and Collaborations: Regional Distribution
Table 18.77 Partnerships and Collaborations: Country-Wise Distribution
Table 18.78 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 18.79 Go-to-Market Strategy: Commonly Used Social Media Platforms
Table 18.80 Go-to-Market Strategy: Online / Print Media
Table 18.81 Go-to-Market Strategy: Promotional Activities through Official Websites
Table 18.82 Go-to-Market Strategy: Different Business Models Adopted
Table 18.83 Go-to-Market Strategy: Promotional Activities through Product Websites
Table 18.84 Global Digital Therapeutics Market, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.85 Global Digital Therapeutics Market: Distribution by Type of Solution, 2020 and 2030
Table 18.86 Digital Therapeutics Market for Standalone Software Applications, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.87 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.88 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.89 Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.90 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.91 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.92 Digital Therapeutics Market for Other Type of Solutions, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.93 Global Digital Therapeutics Market: Distribution by Purpose of Solution, 2020 and 2030
Table 18.94 Digital Therapeutics Market for Medication Replacement Solutions, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.95 Digital Therapeutics Market for Medication Augmentation Solutions, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.96 Global Digital Therapeutics Market: Distribution by Type of Therapy, 2020 and 2030
Table 18.97 Digital Therapeutics Market for Curative Therapy, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.98 Digital Therapeutics Market for Preventive Therapy, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.99 Global Digital Therapeutics Market: Distribution by Business Model, 2020 and 2030
Table 18.100 Digital Therapeutics Market for B2C Model (Patients and, Caregivers), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.101 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.102 Global Digital Therapeutics Market: Distribution by Therapeutic Area, 2020 and 2030
Table 18.103 Digital Therapeutics Market for Cardiovascular Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.104 Digital Therapeutics Market for Chronic Pain, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.105 Digital Therapeutics Market for Mental Health Problems, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.106 Digital Therapeutics Market for Metabolic Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.107 Digital Therapeutics Market for Neurological Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.108 Digital Therapeutics Market for Respiratory Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.109 Digital Therapeutics Market for Sleep Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.110 Digital Therapeutics Market for Substance Use Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.111 Digital Therapeutics Market for Other Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.112 Global Digital Therapeutics Market: Distribution by Geography, 2020 and 2030
Table 18.113 Digital Therapeutics Market in North America, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.114 Digital Therapeutics Market in the US, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.115 Digital Therapeutics Market in Canada, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.116 Digital Therapeutics Market in Europe, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.117 Digital Therapeutics Market in France, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.118 Digital Therapeutics Market in Germany, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.119 Digital Therapeutics Market in Italy, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.120 Digital Therapeutics Market in Spain, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.121 Digital Therapeutics Market in the UK, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.122 Digital Therapeutics Market in Rest of Europe, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.123 Digital Therapeutics Market in Asia-Pacific, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.124 Digital Therapeutics Market in Australia, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.125 Digital Therapeutics Market in China, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.126 Digital Therapeutics Market in India, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.127 Digital Therapeutics Market in Japan, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.128 Digital Therapeutics Market in South Korea, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.129 Digital Therapeutics Market in Rest of Asia-Pacific, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.130 Digital Therapeutics Market in Rest of the World, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.131 Digital Therapeutics Market 2030-2030: Conservative, Base and Optimistic Scenarios: COVID-19 Impact Informed Scenario (USD Billion)
Table 18.132 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Table 18.133 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Table 18.134 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Target Disease Indication
Table 18.135 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Therapeutic Area
Table 18.136 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Year of Establishment
Table 18.137 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Company Size
Table 18.138 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Location of Headquarters
Table 18.139 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Number of Instances by Year
Table 18.140 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested (USD Million)
Table 18.141 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Instances by Type of Funding
Table 18.142 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 18.143 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Funding Instances
Table 18.144 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested (USD Million)
Table 18.145 Remote Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Funding Instances
The following companies and organizations have been mentioned in the report.
Discounts available for multiple report purchases
sales@rootsanalysis.com